


Modern Pharmaceutics

Third Edition, Revised and Expanded



edited by
Gilbert S. Banker
Christopher T. Rhodes

Modern Pharmaceutics

Third Edition, Revised and Expanded

edited by

Gilbert S. Banker

*University of Iowa
Iowa City, Iowa*

Christopher T. Rhodes

*University of Rhode Island
Kingston, Rhode Island*



MARCEL DEKKER, INC.

NEW YORK • BASEL • HONG KONG

Library of Congress Cataloging-in-Publication Data

Modern pharmaceuticals / edited by Gilbert S. Banker, Christopher T. Rhodes.—3rd ed., rev. and expanded.

p. cm.—(Drugs and the pharmaceutical sciences ; v. 72)

Includes bibliographical references and index.

ISBN 0-8247-9371-4 (alk. paper)

1. Drugs—Dosage forms. 2. Biopharmaceutics.

3. Pharmacokinetics. 4. Pharmaceutical industry—Quality control.

I. Banker, Gilbert S. II. Rhodes, Christopher T. III. Series.

RS200.M63 1995

615'.1—dc20

95-33238

CIP

The publisher offers discounts on this book when ordered in bulk quantities. For more information, write to Special Sales/Professional Marketing at the address below.

This book is printed on acid-free paper.

Copyright © 1996 by Marcel Dekker, Inc. All Rights Reserved.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

Marcel Dekker, Inc.

270 Madison Avenue, New York, New York 10016

Current printing (last digit)

10 9 8 7 6 5 4

PRINTED IN THE UNITED STATES OF AMERICA

Parenteral Products

James C. Boylan

Abbott Laboratories, Abbott Park, Illinois

Alan L. Fites

Fites Consulting, Greenwood, Indiana

Steven L. Nail

Purdue University, West Lafayette, Indiana

I. INTRODUCTION

The first official injection (morphine) appeared in the *British Pharmacopoeia (BP)* of 1867. It was not until 1898 when cocaine was added to the *BP* that sterilization was attempted. In this country, the first official injections may be found in the *National Formulary (NF)*, published in 1926. Monographs were included for seven sterile glass-sealed ampoules. The *United States Pharmacopeia (USP)* published in the same year contained a chapter on sterilization, but no monographs for ampoules. The current *USP* contains monographs for over 400 injectable products [1].

Parenteral administration of drugs by intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes is now an established and essential part of medical practice. Advantages for parenterally administered drugs include the following: rapid onset; predictable effect; predictable and nearly complete bioavailability; and avoidance of the gastrointestinal tract (GIT), and hence, the problems of variable absorption, drug inactivation, and GI distress. In addition, the parenteral route provides reliable drug administration in very ill or comatose patients.

The pharmaceutical industry directs considerable effort toward maximizing the usefulness and reliability of oral dosage forms in an effort to minimize the need for parenteral administration. Factors that contribute to this include certain disadvantages of the parenteral route, including the frequent pain and discomfort of injections, with all the psychological fears associated with "the needle," plus the realization that an incorrect drug or dose is often harder or impossible to counteract when it has been given parenterally (particularly intravenously), rather than orally.

In recent years, parenteral dosage forms, especially IV forms, have gained immensely in use. The reasons for this growth are many and varied, but they can be summed up as (a) new and better parenteral administration techniques; (b) new forms of nutritional therapy, such as intravenous lipids, amino acids, and trace metals; (c) the need for simultaneous administration of multiple drugs in hospitalized patients receiving IV therapy, (d) the extension of parenteral

therapy into the home; and (e) an increasing number of drugs that can be administered only by a parenteral route.

Many important drugs are available only as parenteral dosage forms. Notable among these are biotechnology drugs; insulin; several cephalosporin antibiotic products; and drugs such as heparin, protamine, and glucagon. In addition, other drugs, such as lidocaine hydrochloride and many anticancer products, are used principally as parenterals. The reasons that certain drugs are administered largely or exclusively by the parenteral route are very inefficient or unreliable absorption from the GIT, destruction or inactivation in the GIT, extensive mucosal or first-pass metabolism following oral administration, or clinical need in particular medical situations for rapid, assured high blood and tissue levels.

Along with this astounding growth in the use of parenteral medications, the hospital pharmacist has become a very knowledgeable, key individual in most hospitals, having responsibility for hospital-wide IV admixture programs, parenteral unit-dose packaging, and often central surgical supply. By choice, by expertise, and by responsibility, the pharmacist has accumulated the greatest fund of information about parenteral drugs—not only their clinical use, but also their stability, incompatibilities, methods of handling and admixture, and proper packaging. More and more, nurses and physicians are looking to the pharmacist for guidance on parenteral products.

To support the institutional pharmacist in preparing IV admixtures (which typically involves adding one or more drugs to large-volume parenteral fluids), equipment manufacturers have designed laminar flow units, electromechanical compounding units, transfer devices, and filters specifically adaptable to a variety of hospital programs.

The nurse and physician have certainly not been forgotten either. A wide spectrum of IV and IM administration devices and aids have been made available in recent years for bedside use. Many innovative practitioners have made suggestions to industry that have resulted in product or technique improvements, particularly in IV therapy. The use of parenteral products is growing at a very significant rate in nonhospital settings, such as outpatient surgical centers and homes. The reduction in costs associated with outpatient and home care therapy, coupled with advances in drugs, dosage forms, and delivery systems, has caused a major change in the administration of parenteral products [2].

II. ROUTES OF PARENTERAL ADMINISTRATION

The routes of parenteral administration of drugs are (a) subcutaneous, (b) intramuscular, and (c) intravenous; other more specialized routes are (d) intrathecal, (e) intracisternal, (f) intra-arterial, (g) intraspinal, (h) intraepidural, and (i) intradermal. The intradermal route is not typically used to achieve systemic drug effects. The similarities and differences of the routes or their definitions are highlighted in Table 1. The major routes will be discussed separately.

A. The Subcutaneous Route

Lying immediately under the skin is a layer of fat, the superficial fascia (see Fig. 1 in Chapter 8), that lends itself to safe administration of a great variety of drugs, including vaccines, insulin, scopolamine, and epinephrine. Subcutaneous (SC; also SQ or sub-Q) injections are usually administered in volumes up to 2 ml using a 1/2- to 1-in. 22-gauge (or smaller) needle. Care must be taken to ensure that the needle is not in a vein. This is done by lightly pulling back on the syringe plunger (aspiration) before making the injection. If the needle is inadvertently located in a vein, blood will appear in the syringe and the injection should not be made. The injection site may be massaged after injection to facilitate drug absorption. Drugs given by this

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.